BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE : revenue, balance sheet and financial ratios

BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE is a French company founded 42 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LYON (69007), this company of category ETI shows in 2024 a revenue of 679.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE (SIREN 590800215)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 679 595 898 € 690 636 898 € 577 752 570 € 580 624 889 € 592 560 893 € 571 948 003 € 862 328 182 € 778 070 292 € 865 150 000 €
Net income 68 548 142 € 68 358 765 € 74 444 473 € 113 392 041 € 61 380 007 € 353 446 457 € 403 632 329 € 43 154 555 € 1 723 556 000 €
EBITDA -27 002 754 € -54 910 834 € -39 475 085 € -63 126 379 € -72 411 924 € -112 568 065 € 136 872 386 € 113 723 736 € 184 244 000 €
Net margin 10.1% 9.9% 12.9% 19.5% 10.4% 61.8% 46.8% 5.5% 199.2%

Revenue and income statement

In 2024, BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE achieves revenue of 679.6 M€. Activity remains stable over the period (CAGR: -3.0%). Slight decline of -2% vs 2023. After deducting consumption (257.3 M€), gross margin stands at 422.3 M€, i.e. a rate of 62%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -27.0 M€, representing -4.0% of revenue. Positive scissor effect: EBITDA margin improves by +4.0 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 68.5 M€, i.e. 10.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

679 595 898 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

422 302 553 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-27 002 754 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

104 933 850 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

68 548 142 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-4.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 17%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.8 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 11.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

17.17%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

57.239%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

11.378%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

1.795

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

48.4%

Solvency indicators evolution
BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE

Sector positioning

Debt ratio
17.17 2024
2022
2023
2024
Q1: 0.0
Med: 5.92
Q3: 43.75
Average

In 2024, the debt ratio of BOEHRINGER INGELHEIM ANIM... (17.17) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
57.24% 2024
2022
2023
2024
Q1: 28.05%
Med: 51.52%
Q3: 72.2%
Good

In 2024, the financial autonomy of BOEHRINGER INGELHEIM ANIM... (57.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
1.79 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.01 years
Q3: 1.74 years
Average

In 2024, the repayment capacity of BOEHRINGER INGELHEIM ANIM... (1.79) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 171.41. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

171.415

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-47.615

Liquidity indicators evolution
BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE

Sector positioning

Liquidity ratio
171.41 2024
2022
2023
2024
Q1: 120.09
Med: 209.86
Q3: 363.93
Average -14 pts over 3 years

In 2024, the liquidity ratio of BOEHRINGER INGELHEIM ANIM... (171.41) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-47.62x 2024
2022
2023
2024
Q1: 0.0x
Med: 1.78x
Q3: 10.15x
Watch

In 2024, the interest coverage of BOEHRINGER INGELHEIM ANIM... (-47.6x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 94 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 80 days. The company must finance 14 days of gap between collections and payments. Inventory turnover is 234 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 164 days of revenue, i.e. 309.3 M€ to permanently finance. Over 2016-2024, WCR increased by +67%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

309 304 481 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

94 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

80 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

234 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

164 j

WCR and payment terms evolution
BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE

Positioning of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 13 676 674€ to 42 036 751€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
13676k€ 30877k€ 42036k€
30 877 957 € Range: 13 676 674€ - 42 036 751€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de préparations pharmaceutiques)

Compare BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE

What is the revenue of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE ?

The revenue of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE in 2024 is 679.6 M€.

Is BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE profitable?

Yes, BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE generated a net profit of 68.5 M€ in 2024.

Where is the headquarters of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE ?

The headquarters of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE is located in LYON (69007), in the department Rhone.

Where to find the tax return of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE ?

The tax return of BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE operate?

BOEHRINGER INGELHEIM ANIMAL HEALTH FRANCE operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.